Clinical trials: Advanced Solid Tumor, completed
Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma
Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer
This Phase I/Il studies the side effects of endobronchial ultrasound guided interstitial photodynamic therapy work in treating patients with lung cancer that has spread to nearby tissues or lymph nodes.
- Conditions
- Locally Advanced Lung Carcinoma, Non-Small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Stage III Lung Cancer AJCC v8
- Trial name
- NCT03735095
- Testing
- Porfimer Sodium, Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Roswell Park Cancer Institute
Advanced/Metastatic Solid Malignancies
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
The study is to evaluate preliminary anti-tumor activity (overall response rate, ORR) of IBI308 monotherapy in subjects with advanced/metastatic solid malignancies.
- Trial name
- NCT03568539
- Testing
- IBI308
- Where
- 7 sites in United States
- Volunteers
- 39 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Advanced Solid Tumors
A Study to Determine the Metabolism and Elimination of Carbon-14 Labeled Eribulin Acetate (14C-Eribulin) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the metabolism and elimination of carbon-14 labeled eribulin acetate (14C-eribulin) in patients with advanced solid tumors.
- Trial name
- NCT00908908
- Testing
- eribulin
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Eisai Inc.
Advanced Solid Tumor
QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors
The purpose of this study is to assess whether eribulin mesylate (E7389) has an impact on the electrocardiogram (ECG) with focus on cardiac repolarization, as measured by QT/QTc interval as well as through a…
- Trial name
- NCT01106248
- Testing
- Eribulin Mesylate
- Where
- 2 sites in France
- Volunteers
- 26 people
- Sponsor
- Eisai Limited
Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma, Ependymoma
- Trial name
- NCT03220035
- Testing
- Laboratory Biomarker Analysis, Vemurafenib
- Where
- 116 sites in United States, Puerto Rico
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Advanced Solid Tumor
A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors
This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Metastatic Solid Tumor
- Trial name
- NCT04761198
- Testing
- Etigilimab, Nivolumab
- Where
- 16 sites in United States, United Kingdom
- Volunteers
- 76 people
- Sponsor
- Mereo BioPharma
Ovarian Cancer, Epithelial Ovarian Cancer
A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment
The study seeks to assess the safety, pharmacodynamics, pharmacokinetics and efficacy of belinostat (PXD101) administered in combination with carboplatin or paclitaxel or both in patients with solid tumours followed by maximum…
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Bladder Cancer
- Trial name
- NCT00421889
- Testing
- belinostat, Paclitaxel, Carboplatin
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 80 people
- Sponsor
- Valerio Therapeutics
Advanced Malignancies, Non-small-cell Lung Cancer
Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies
This is a Phase 1b/2 protocol to evaluate pharmacokinetics, safety, efficacy, and pharmacodynamics of PF-06801591, a programmed death-1(PD-1) antagonist monoclonal antibody (mAb) in participants with advanced malignancies.
- Trial name
- NCT04181788
- Testing
- PF-06801591
- Where
- 49 sites in China, Japan and 4 more
- Volunteers
- 155 people
- Sponsor
- Pfizer
Advanced Solid Tumors, Lymphomas
A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas
The purpose of this study was to determine the safety profile, maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and to characterize the pharmacokinetic (PK) profile of alisertib twice daily (BID) dosing for 7 days…
- Trial name
- NCT01512758
- Testing
- Alisertib
- Where
- Singapore
- Volunteers
- 36 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Neoplasms
GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors
The purpose of this study is to evaluate if the combination of GSK3359609 and tremelimumab is safe and tolerable (Part 1) and provides significant survival benefit to subjects with relapsed/refractory (R/R) Head and Neck Squamous…
- Trial name
- NCT03693612
- Testing
- feladilimab, Tremelimumab, Docetaxel
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 26 people
- Sponsor
- GlaxoSmithKline
Malignant Solid Tumor, Metastatic EphA2 Positive Cancer
Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
This was a Phase 1, dose-escalation, non-randomized, open-label, single-center study of DS-8895a in patients with advanced or metastatic Ephrin type-A receptor 2 (EphA2)-positive cancers.
- Trial name
- LUD2014-002 (NCT02252211)
- Testing
- DS-8895a 1 mg/kg, DS-8895a 3 mg/kg, DS-8895a 10 mg/kg
- Where
- Australia
- Volunteers
- 9 people
- Sponsor
- Ludwig Institute for Cancer Research
Tumors
A Study of IMC-A12 in Advanced Solid Tumors
In this study, participants will initially receive intravenous (IV) cixutumumab (IMC-A12) every 2 weeks or every 3 weeks for 6 weeks (one cycle).
- Trial name
- NCT01007032
- Testing
- Cixutumumab
- Where
- Japan
- Volunteers
- 21 people
- Sponsor
- Eli Lilly and Company
Tumors
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
This is a multicenter, open-label, non-randomized Phase 1 study in participants with advanced solid tumors, excluding hepatocellular carcinoma (HCC), that have progressed after treatment with approved therapies, or for which…
- Trial name
- NCT02686164
- Testing
- Lenvatinib, Midazolam
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Eisai Inc.
Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
- Trial name
- STRONG (NCT03084471)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Where
- 79 sites in United States, Canada and 6 more
- Volunteers
- 867 people
- Sponsor
- AstraZeneca
Tumors
Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours
The purpose of this study is to determine whether doses of 30 mg and 45 mg AZD2171 can be well tolerated without significant drug withdrawal when accompanied by a suitable hypertension management strategy or dose reduction.
- Trial name
- NCT00264004
- Testing
- AZD2171
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Neoplasm Metastasis, Advanced Tumors
Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours
This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy.
- Conditions
- Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors
- Trial name
- NCT03697304
- Testing
- Ezabenlimab, BI 754111, BI 836880
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 211 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer, Ovarian Cancer
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
This was a Phase 1, open-label, nonrandomized, multicenter study of durvalumab and tremelimumab in subjects with advanced cancers who were not eligible for, declined, or failed standard treatment.
- Conditions
- Breast Cancer, Ovarian Cancer, Colorectal Cancer, Cervical Cancer
- Trial name
- NCT01975831
- Testing
- Durvalumab, Tremelimumab
- Where
- 6 sites in United States
- Volunteers
- 104 people
- Sponsor
- Ludwig Institute for Cancer Research
Advanced Solid Tumours
A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer
The study is investigating efficacy, safety and tolerability of DNA-damage Response Agents (or Combinations), in participants with advanced/metastatic solid malignancies whose tumours contain molecular alterations
- Trial name
- NCT04564027
- Testing
- Ceralasertib
- Where
- 18 sites in United States, France and 1 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
First-in-Human Study of IMGC936 in Participants With Advanced Solid Tumors
This study is a Phase 1/2, first-in-human, open-label, dose-escalation, and expansion study designed to characterize the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of IMGC936…
- Trial name
- NCT04622774
- Testing
- IMGC936
- Where
- 13 sites in United States, Italy and 1 more
- Volunteers
- 56 people
- Sponsor
- ImmunoGen, Inc.